Stock Track | REMEGEN Plummets 5.12% Intraday on Lock-up Expiry Fears, Weak Earnings, and Sector Weakness

Stock Track05-11

REMEGEN's stock price plummeted 5.12% during intraday trading on Monday.

The sharp decline is attributed to market concerns over a significant lock-up expiry event scheduled for June 30, which will see approximately 192.8 million restricted shares become eligible for trading. This represents 34.16% of the company's total share capital and is expected to more than double the current free float, raising fears of concentrated selling pressure.

Additionally, the company's recent financial performance has weighed on sentiment. REMEGEN reported a first-quarter net profit attributable to shareholders of approximately RMB 328 million, a sharp quarter-over-quarter decline of roughly 73%. Furthermore, its adjusted net profit, excluding non-recurring items, remained in loss territory, indicating ongoing fundamental challenges. The stock was also dragged down by broad-based weakness in the Biotechnology sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184350379?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 09:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184350379","market":"us","top_or_hot":-1,"title":"Stock Track | REMEGEN Plummets 5.12% Intraday on Lock-up Expiry Fears, Weak Earnings, and Sector Weakness","media":"Stock Track","content":"<p>REMEGEN's stock price plummeted 5.12% during intraday trading on Monday.</p><p>The sharp decline is attributed to market concerns over a significant lock-up expiry event scheduled for June 30, which will see approximately 192.8 million restricted shares become eligible for trading. This represents 34.16% of the company's total share capital and is expected to more than double the current free float, raising fears of concentrated selling pressure.</p><p>Additionally, the company's recent financial performance has weighed on sentiment. REMEGEN reported a first-quarter net profit attributable to shareholders of approximately RMB 328 million, a sharp quarter-over-quarter decline of roughly 73%. Furthermore, its adjusted net profit, excluding non-recurring items, remained in loss territory, indicating ongoing fundamental challenges. The stock was also dragged down by broad-based weakness in the Biotechnology sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Plummets 5.12% Intraday on Lock-up Expiry Fears, Weak Earnings, and Sector Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Plummets 5.12% Intraday on Lock-up Expiry Fears, Weak Earnings, and Sector Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-11 09:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN's stock price plummeted 5.12% during intraday trading on Monday.</p><p>The sharp decline is attributed to market concerns over a significant lock-up expiry event scheduled for June 30, which will see approximately 192.8 million restricted shares become eligible for trading. This represents 34.16% of the company's total share capital and is expected to more than double the current free float, raising fears of concentrated selling pressure.</p><p>Additionally, the company's recent financial performance has weighed on sentiment. REMEGEN reported a first-quarter net profit attributable to shareholders of approximately RMB 328 million, a sharp quarter-over-quarter decline of roughly 73%. Furthermore, its adjusted net profit, excluding non-recurring items, remained in loss territory, indicating ongoing fundamental challenges. The stock was also dragged down by broad-based weakness in the Biotechnology sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1184350379","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184350379","pubTimestamp":1778464757,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN's stock price plummeted 5.12% during intraday trading on Monday.The sharp decline is attributed to market concerns over a significant lock-up expiry event scheduled for June 30, which will...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"个股追踪|REMEGEN盘中暴跌5.12%，因禁售期担忧、盈利疲弱、板块疲软","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN's stock price plummeted 5.12% during intraday trading on Monday.The sharp decline is attributed to market concerns over a significant lock-up expiry event scheduled for June 30, which will see approximately 192.8 million restricted shares become eligible for trading. This represents 34.16% of the company's total share capital and is expected to more than double the current free float, raising fears of concentrated selling pressure.Additionally, the company's recent financial performance has weighed on sentiment. REMEGEN reported a first-quarter net profit attributable to shareholders of approximately RMB 328 million, a sharp quarter-over-quarter decline of roughly 73%. Furthermore, its adjusted net profit, excluding non-recurring items, remained in loss territory, indicating ongoing fundamental challenges. The stock was also dragged down by broad-based weakness in the Biotechnology sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184350379","isCrawlerRequest":true}